CytoDyn Inc. (CYDY)
-OTC Markets | Prev Close: | 0.70 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 0.41 - 2.10 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 30,711 |
|---|
| Market Cap: | 21.63M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.36 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- CYTODYN INC Files SEC form 8-K, Change in Directors or Principal OfficersEDGAR Online(Fri, May 17)
- CytoDyn Announces Important Milestone Achieved to Initiate Phase IIb StudiesBusiness Wire(Mon, Apr 29)
- CYTODYN INC FinancialsEDGAR Online Financials(Thu, Apr 18)
- CYTODYN INC Files SEC form 8-K, Regulation FD DisclosureEDGAR Online(Tue, Apr 16)
- CYTODYN INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, Apr 12)
- CytoDyn to Attend BIOCOM Global Life Sciences Partnering ConferenceBusiness Wire(Wed, Feb 27)
- CytoDyn Announces Collaboration with Dr. Bruce Torbett, The Scripps Research Institute, to study PRO 140 in a Pre-exposure Prophylaxis (PrEP) Model of HIV InfectionBusiness Wire(Tue, Feb 26)
- CytoDyn Announces Investor Update Conference Call on Friday, February 22Business Wire(Tue, Feb 19)
- CYTODYN INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and ExhibitsEDGAR Online(Mon, Jan 14)
- CytoDyn to Attend 31st Annual J.P. Morgan Healthcare ConferenceBusiness Wire(Mon, Jan 7)
- CytoDyn Appoints Former Ambassador to Bahrain as Middle East Business ConsultantBusiness Wire(Wed, Jan 2)
- CYTODYN INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of SecuritEDGAR Online(Tue, Dec 18)
- CytoDyn Elects Two New Directors and Appoints New Chief Financial OfficerBusiness Wire(Tue, Dec 18)
- CytoDyn Expands Outreach Through Increased Online PresenceBusiness Wire(Fri, Dec 7)
- CYTODYN INC Files SEC form 8-K, Change in Directors or Principal OfficersEDGAR Online(Tue, Nov 20)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(0-00-31)
: | N/A |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
CytoDyn Inc., a development stage biotechnology company, focuses on the discovery and development of therapeutic monoclonal antibodies to treat human immunodeficiency virus (HIV) infection.
View More 
0.80%